Showing 5741-5750 of 10820 results for "".
- Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co. Ltd. for Qbrexza in South Korea, Other Asian Nationshttps://practicaldermatology.com/news/journey-medical-corporation-enters-into-an-exclusive-license-agreement-with-maruho-co-ltd-for-qbrexza-in-south-korea-other-asian-nations/2461983/Journey Medical Corporation has entered into an exclusive license agreement with Maruho Co., Ltd. for Qbrexza in South Korea and Other Asian Nations. Maruho Co., Ltd. is Journey’s exclusive licensing partner that developed and is commercializing Qbrexza (Rapifort) in Japan.&n
- Christopher G. Bunick, MD, PhD, Receives the American Acne and Rosacea Society's 2023 Research Scholar Awardhttps://practicaldermatology.com/news/christopher-g-bunick-md-phd-receives-american-acne-and-rosacea-society-announces-2023-research-scholar-award/2461962/Christopher G. Bunick, MD, PhD, has received The American Acne and Rosacea Society’s (AARS) 2023 Research Scholar Award. Dr. Bunick is an Associate Professor of Dermatology at Yale University School of Medicine and a member of the Practical Dermatology magazine editorial board.</
- Merz Aesthetics to Distribute AccuVein’s Visualization Systemhttps://practicaldermatology.com/news/merz-aesthetics-to-distribute-accuveins-visualization-system/2461829/Merz Aesthetics is now the sole authorized distributor of AccuVein’s vein visualization system in the U.S. aesthetics market. A limited initial AccuVein field pilot yielded positive results and significant expansion of both new customers and Merz Aesthetics portfolio adoption. Bas
- Gentle Cleansers Kill Viruses as Effectively as Harsh Soapshttps://practicaldermatology.com/news/gentle-cleansers-kill-viruses-as-effectively-as-harsh-soaps/2461780/Gentle cleansers are just as effective in killing viruses – including coronavirus - as harsh soaps, a new study out University of Sheffield experts has found. Scientists from the University of Sheffield’s Sh
- Orlucent Receives FDA Breakthrough Device Designation for Handheld Mole Imaging Systemhttps://practicaldermatology.com/news/orlucent-receives-fda-breakthrough-device-designation-for-handheld-mole-imaging-system/2461733/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Orlucent’s Skin Fluorescence Imaging System. The Orlucent system is a handheld point-of-care molecular-based imaging system designed to noninvasively identify and clinically assess the pres
- Dr. Suneel Chilukuri Named Hydrinity Accelerated Skin Science’s Chief Medical Advisorhttps://practicaldermatology.com/news/dr-suneel-chilukuri-named-hydrinity-accelerated-skin-sciences-chief-medical-advisor/2461692/Suneel Chilukuri, MD, is Hydrinity Accelerated Skin Science’s new Chief Medical Advisor. In this role, Dr. Chilukuri will chair the Hydrinity Accelerated Skin Science Medical Advisory Board. He will aid product development as well as develop and oversee all clinica
- Cetaphil Celebrates Sensitive Skin with a Month of Skin Science Educationhttps://practicaldermatology.com/news/cetaphil-celebrates-sensitive-skin-with-a-month-of-skin-science-education/2461610/Cetaphil is ringing in the 2nd Annual Sensitive Skin Awareness initiative globally with a month of skin science education. Activating under the brand's campaign, "We Do Skin. You Do You," the global science effort will arm consumers with guidance on how to i
- BeautyHealth Acquires SkinStylushttps://practicaldermatology.com/news/beautyhealth-acquires-skinstylus/2461579/The Beauty Health Company is set to acquire SkinStylus, a US Food and Drug Adminstrayion -cleared microneedling device. The agreement represents a key step forward in BeautyHealth’s portfolio build-up strategy. Upon successful integration of SkinStylus into the BeautyHealth
- Neauvia Scores CE Marking Under the European Union’s New MDR for Facial Dermal Filler Linehttps://practicaldermatology.com/news/neauvia-scores-ce-marking-under-the-european-unions-new-mdr-for-facial-dermal-filler-line/2461564/Neauvia scored CE marking under the European Union’s new MDR (Medical Device Regulation) for its range of facial dermal fillers products, making it the first medical aesthetics business to receive such certification in Europe. The new regulation aims to create ‘a robus
- Experts React to Approval of Pfizer’s CIBINQO for Teens With Refractory ADhttps://practicaldermatology.com/news/fda-oks-pfizers-cibinqo-for-teens-with-refractory-ad/2461560/The US FDA has approved a supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib, Pfizer). This move expands the drug's indication to include adolescents (12 to < 18 years) with refractory, moderate to severe atopic dermatitis (AD) whose disease is not adequately contr